Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Register now for the “Q4 Earnings Season Wrap-Up.”
Join stock market expert Marc Chaikin (the creator of Chaikin Money Flow) and Explosive Options’ Bob Lang for a special earnings season wrap-up.

You’ll find out the biggest takeaways from recent earnings results and what it means for the market—and YOUR money. 

Menu

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,297,834
  • Shares Outstanding, K 54,694
  • Annual Sales, $ 35,430 K
  • Annual Income, $ -335,640 K
  • 36-Month Beta 2.62
  • Price/Sales 168.86
  • Price/Cash Flow N/A
  • Price/Book 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -2.83
  • Number of Estimates 12
  • High Estimate -2.55
  • Low Estimate -3.20
  • Prior Year -2.52
  • Growth Rate Est. (year over year) -12.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
116.72 +9.60%
on 01/23/19
139.99 -8.62%
on 02/05/19
-2.04 (-1.57%)
since 01/18/19
3-Month
87.49 +46.21%
on 12/24/18
139.99 -8.62%
on 02/05/19
+11.06 (+9.46%)
since 11/21/18
52-Week
87.49 +46.21%
on 12/24/18
236.17 -45.83%
on 03/13/18
-79.48 (-38.32%)
since 02/21/18

Most Recent Stories

More News
Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tyson Foods, Inc. (NYSE:TSN),...

YEXT : 18.17 (-5.02%)
SPR : 96.14 (-1.88%)
BLUE : 127.39 (-4.53%)
SOLO : 4.09 (-2.85%)
CUZ : 9.53 (-0.31%)
TSN : 62.95 (-1.02%)
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma...

BLUE : 127.39 (-4.53%)
ABBV : 78.42 (-1.96%)
AMGN : 185.20 (-0.92%)
BMY : 50.21 (-2.12%)
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

BAYRY : 19.1700 (-1.19%)
BLUE : 127.39 (-4.53%)
REGN : 417.55 (-1.17%)
SNY : 41.32 (-1.97%)
Bluebird Bio Inc Shares Up 16.2% Since SmarTrend's Buy Recommendation (BLUE)

SmarTrend identified an Uptrend for Bluebird Bio Inc (NASDAQ:BLUE) on January 11th, 2019 at $116.82. In approximately 4 weeks, Bluebird Bio Inc has returned 16.21% as of today's recent price of $135.76....

BLUE : 127.39 (-4.53%)
Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

CELG : 88.70 (-1.88%)
BLUE : 127.39 (-4.53%)
XLRN : 42.02 (+0.05%)
BMY : 50.21 (-2.12%)
Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged...

BLUE : 127.39 (-4.53%)
Uptrend Call Working As Bluebird Bio Inc Stock Rises 8.1% (BLUE)

SmarTrend identified an Uptrend for Bluebird Bio Inc (NASDAQ:BLUE) on January 11th, 2019 at $116.82. In approximately 2 weeks, Bluebird Bio Inc has returned 8.09% as of today's recent price of $126.27....

BLUE : 127.39 (-4.53%)
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

CELG : 88.70 (-1.88%)
BLUE : 127.39 (-4.53%)
ALNY : 76.53 (-1.57%)
REGN : 417.55 (-1.17%)
AMGN : 185.20 (-0.92%)
5 Best Biotech Bets Likely to Outperform Estimates in Q4

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

CELG : 88.70 (-1.88%)
BLUE : 127.39 (-4.53%)
LLY : 122.51 (-0.12%)
ALNY : 76.53 (-1.57%)
LOXO : 234.80 (+0.06%)
REGN : 417.55 (-1.17%)
AMGN : 185.20 (-0.92%)
BMY : 50.21 (-2.12%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird bio" or "the Company") (NASDAQ: BLUE)...

BLUE : 127.39 (-4.53%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade BLUE with:

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 139.97
1st Resistance Point 136.71
Last Price 127.32
1st Support Level 130.48
2nd Support Level 127.51

See More

52-Week High 236.17
Fibonacci 61.8% 179.37
Fibonacci 50% 161.83
Fibonacci 38.2% 144.28
Last Price 127.32
52-Week Low 87.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar